摘要
结直肠癌是目前世界上常见的恶性肿瘤之一。近年来,化疗药物的使用在结直肠癌治疗中取得了较大进展,但治疗效果和不良反应仍然存在个体化差异。遗传因素是造成药物反应存在个体差异的主要原因。检测遗传标志如单核苷酸多态(single nucleotide polymorphism,SNP)可以预测患者的治疗疗效和不良反应,为结直肠癌患者的个体化治疗提供依据。目前,研究者们已通过候选基因策略和全基因组策略找到一些用于预测结直肠癌药物疗效和不良反应的遗传标志。本文将根据两种策略的研究结果概述结直肠癌药物遗传学的最新研究进展。
Colorectal cancer is one of the most common malignant neoplasms all over the world.In recent years,there has been considerable progress in the use of chemotherapy for colorectal cancer.However,variations of clinical outcomes and adverse events induced by chemotherapy still exist in different patients.The genetic factors are the major causes for the individual variations of the effi cacy of chemotherapeutic drugs.The genetic markers,such as single nucleotide polymorphisms（SNPs）,can be used as a predictor for the clinical outcomes and adverse events of chemotherapy,and provide evidence for the individual therapy of colorectal cancer.Researchers have found some genetic markers to predict effi cacy and adverse events induced by chemotherapeutic drugs in patients with colorectal cancer by using the candidate gene strategy and the genome-wide association strategy.This review summarizes the advances in pharmacogenetics in chemotherapy of colorectal cancer on the basis of these two research strategies.
出处
《肿瘤》
CAS
CSCD
北大核心
2014年第11期1069-1074,共6页
Tumor
关键词
结直肠肿瘤
药物疗法
遗传标记
多态性
单核苷酸
Colorectal neoplasms
Drug therapy
Genetic markers
Polymorphism,single nucleotide
